CSI Signs International Distribution Agreement With OrbusNeich


July 16, 2018—Cardiovascular Systems, Inc (CSI) announced an exclusive international distribution agreement with OrbusNeich to sell CSI's coronary and peripheral orbital atherectomy systems (OAS) outside the United States and Japan. OrbusNeich manufactures and sells an extensive portfolio of coronary and peripheral products including stents, balloons, and microcatheters. The company operates 12 regional sales offices throughout the world and their products are currently sold in more than 60 countries.

CSI advised that it will focus its international efforts on physician training and education to support the expanded use of orbital atherectomy.

OrbusNeich stated that the company intends to introduce CSI’s orbital atherectomy systems in multiple countries in Europe and Southeast Asia in 2018, focusing initially on those countries that recognize FDA approvals in addition to European markets where CSI has CE Mark approval for its peripheral technology.

In January 2018, CSI announced that it was the exclusive United States distributor for OrbusNeich balloon products. CSI will offer a full line of semicompliant, noncompliant, and specialty balloons for both coronary and peripheral vascular procedures. OrbusNeich percutaneous coronary intervention balloons include the Sapphire II Pro. Currently, CSI offers both the 1.0- to 4.0-mm Sapphire II Pro and the 2.0- to 4.0-mm Sapphire NC Plus coronary balloons.

Additionally, CSI announced in November 2016 that Medikit, Co., Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral OAS in Japan.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.